The estimated Net Worth of Capital, Llcjones Evan/ Fa ... is at least $11.5 Million dollars as of 18 July 2017. Capital Fa owns over 1,875,000 units of Opgen Inc stock worth over $11,474,820 and over the last 7 years Capital sold OPGN stock worth over $0.
Sign up
Capital Fa OPGN stock SEC Form 4 insiders trading
Capital has made over 1 trades of the Opgen Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital bought 1,875,000 units of OPGN stock worth $750,000 on 18 July 2017.
The largest trade Capital's ever made was buying 1,875,000 units of Opgen Inc stock on 18 July 2017 worth over $750,000. On average, Capital trades about 625,000 units every 0 days since 2017. As of 18 July 2017 Capital still owns at least 5,680,604 units of Opgen Inc stock.
You can see the complete history of Capital Fa stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Opgen Inc
Over the last 9 years, insiders at Opgen Inc have traded over $12,018 worth of Opgen Inc stock and bought 4,331,782 units worth $1,198,700 . The most active insiders traders include Evan/ Fa Jones, Capital, Llcjones Evan/ Fa ... und Capital, Llc J Ven. On average, Opgen Inc executives and independent directors trade stock every 78 days with the average trade being worth of $280,277. The most recent stock trade was executed by Johannes Bacher on 31 March 2023, trading 6,434 units of OPGN stock currently worth $12,997.
What does Opgen Inc do?
opgen, inc. (nasdaq: opgn) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment. using our large and ever-growing acuitas lighthouse® knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. today, through our clia-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. our fda-cleared, ivd products rapidly identify pathogens in positive blood cultures.
What does Opgen Inc's logo look like?
Complete history of Capital Fa stock trades at Opgen Inc
Opgen Inc executives and stock owners
Opgen Inc executives and other stock owners filed with the SEC include:
-
Dr. Oliver Schacht Ph.D.,
CEO, Pres & Director -
Dr. Oliver Schacht,
CEO, Pres & Director -
Timothy C. Dec,
CFO & Corp. Sec. -
Johannes Bacher,
Chief Operating Officer -
Dr. Arne Materna,
MD & CEO of Ares Genetics GmbH -
Derek Joesting,
Sr. VP of US Sales -
Albert Weber,
Chief Financial Officer -
Dr. Achim Plum,
Special Advisor of Ares Genetics GmbH -
Dr. Andreas Posch,
Special Advisor of Ares Genetics GmbH -
Christopher D. Emery,
Chief Commercial Officer for the Americas -
Dr. G. Terrance Walker Ph.D.,
Sr. VP of R&D -
Faranak Atrzadeh,
Chief Marketing & Scientific Affairs Officer -
Michael Farmer,
VP of Marketing -
Vadim Sapiro,
Chief Information Officer -
& Co., Inc.Merck Sharp & Do...,
-
Laurence Mc Carthy,
Director -
Capital, Llc J Ven,
10% owner -
Misti Ushio,
Director -
Timothy J.R. Harris,
Director -
Kevin Krenitsky,
President -
Brian G Atwood,
Director -
Timothy C Dec,
Chief Financial Officer -
Tina Susan Nova,
Director -
Evan/ Fa Jones,
Director -
Capital, Llcjones Evan/ Fa ...,
Chairman and CEOChief Executive Officer -
Vadim M. Sapiro,
Chief Information Officer -
R Don Elsey,
Director -
Matthew Charles Mc Murdo,
Director -
David Natan,
Director -
Avraham Ben Tzvi,
Director -
Mario Crovetto,
Director -
Johannes Bacher,
Chief Operating Officer -
Prabhavathi Fernandes,
Director -
William E. Rhodes,
Director -
Oliver Schacht,
Chief Executive Officer -
Albert Weber,
Chief Finanical Officer -
Yvonne Schlaeppi,
Director -
David E. Lazar,
Chief Executive Officer